These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 31691112)
1. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection. Ellis RJ; Ho JW; Schlick CJR; Merkow RP; Bentrem DJ; Bilimoria KY; Yang AD Ann Surg Oncol; 2020 Mar; 27(3):909-918. PubMed ID: 31691112 [TBL] [Abstract][Full Text] [Related]
2. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival. Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044 [TBL] [Abstract][Full Text] [Related]
3. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer. Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270 [TBL] [Abstract][Full Text] [Related]
4. Type of Resection (Whipple vs. Distal) Does Not Affect the National Failure to Provide Post-resection Adjuvant Chemotherapy in Localized Pancreatic Cancer. Bergquist JR; Ivanics T; Shubert CR; Habermann EB; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB; Truty MJ Ann Surg Oncol; 2017 Jun; 24(6):1731-1738. PubMed ID: 28070725 [TBL] [Abstract][Full Text] [Related]
5. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer. Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466 [TBL] [Abstract][Full Text] [Related]
6. Optimal Adjuvant Treatment Approach After Upfront Resection of Pancreatic Cancer: Revisiting the Role of Radiation Based on Pathologic Features. Moaven O; Clark CJ; Russell GB; Votanopoulos KI; Howerton R; Levine EA; Shen P Ann Surg; 2021 Dec; 274(6):1058-1066. PubMed ID: 31913868 [TBL] [Abstract][Full Text] [Related]
7. Disparities in Receipt of Adjuvant Therapy After Upfront Surgical Resection for Pancreatic Ductal Adenocarcinoma. Anteby R; Blaszkowsky LS; Hong TS; Qadan M Ann Surg Oncol; 2023 Apr; 30(4):2473-2481. PubMed ID: 36585536 [TBL] [Abstract][Full Text] [Related]
8. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis. Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208 [TBL] [Abstract][Full Text] [Related]
9. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410 [TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies. Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242 [TBL] [Abstract][Full Text] [Related]
11. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas. Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382 [TBL] [Abstract][Full Text] [Related]
12. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodenectomy. Hue JJ; Sugumar K; Markt SC; Hardacre JM; Ammori JB; Rothermel LD; Winter JM; Ocuin LM Surgery; 2021 Jul; 170(1):207-214. PubMed ID: 33454134 [TBL] [Abstract][Full Text] [Related]
13. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Hamad A; Underhill J; Ansari A; Thayaparan V; Cloyd JM; Li Y; Pawlik TM; Tsung A; Abushahin L; Ejaz A Surgery; 2022 Jun; 171(6):1464-1470. PubMed ID: 35115154 [TBL] [Abstract][Full Text] [Related]
14. Impact of Different Treatment Modalities on the Outcome of Pancreatic Cancer. Khan M; Ashraf MI; Syed AA; Hanif F J Coll Physicians Surg Pak; 2017 Aug; 27(8):470-474. PubMed ID: 28903837 [TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Mokdad AA; Minter RM; Zhu H; Augustine MM; Porembka MR; Wang SC; Yopp AC; Mansour JC; Choti MA; Polanco PM J Clin Oncol; 2017 Feb; 35(5):515-522. PubMed ID: 27621388 [TBL] [Abstract][Full Text] [Related]
16. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy. Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P Oncology; 2015; 89(1):37-46. PubMed ID: 25766660 [TBL] [Abstract][Full Text] [Related]
17. Multimodality therapy for pancreatic cancer in the U.S. : utilization, outcomes, and the effect of hospital volume. Bilimoria KY; Bentrem DJ; Ko CY; Tomlinson JS; Stewart AK; Winchester DP; Talamonti MS Cancer; 2007 Sep; 110(6):1227-34. PubMed ID: 17654662 [TBL] [Abstract][Full Text] [Related]
18. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Merkow RP; Bilimoria KY; Tomlinson JS; Paruch JL; Fleming JB; Talamonti MS; Ko CY; Bentrem DJ Ann Surg; 2014 Aug; 260(2):372-7. PubMed ID: 24374509 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445 [TBL] [Abstract][Full Text] [Related]
20. Real-world patterns of adjuvant chemotherapy treatment for patients with resected pancreatic adenocarcinoma. Abdel-Rahman O; Spratlin J; Koski S Med Oncol; 2021 Feb; 38(2):18. PubMed ID: 33534008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]